Zacks Investment Research downgraded shares of Cortexyme (NASDAQ:CRTX – Get Rating) from a hold rating to a sell rating in a research note released on Tuesday, Zacks.com reports. According to Zacks, “Cortexyme Inc. is a clinical-stage biopharmaceutical company. It is focused on providing disease-modifying therapeutics to treat Alzheimer’s and other degenerative diseases. The company’s drug […]
Cortexyme (NASDAQ:CRTX – Get Rating) and Immunocore (NASDAQ:IMCR – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, earnings and profitability. Earnings and Valuation This table compares Cortexyme and Immunocore’s top-line revenue, […]
The 2022 International Conference on Alzheimer’s and Parkinson’s Disease ended last weekend, but it reported on numerous research studies and insights into the diseases.
Cortexyme, Inc. (NASDAQ:CRTX – Get Rating) has been assigned a consensus rating of “Hold” from the eight research firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. The […]